Alydia Health specializes in medical devices to treat postpartum hemorrhage. The deal is valued at up to $240 million, including $50 million upfront, $165 million upon the closing of the deal, and $25 million in milestone payments.
“Organon’s acquisition of Alydia Health expands our portfolio into the medical device category and underscores our commitment to identify options for women’s unmet medical needs,” Kevin Ali, CEO of Organon, said in a news release. “This acquisition brings us one step closer to our vision of a better and healthier everyday for every woman around the world.”
Organon spun off from Merck June 3.
Read the full news release here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.